contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


the-administrative-court-rejects-the-healthcare-providers-appeal-to-remove-the-requirement-for-millennium-in-primary-care-in-vgr

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Carasent är ett IT-bolag. Bolaget levererar ett brett utbud av produkter och tjänster inom kommunikation och IT-infrastruktur särskilt inriktade mot sjukvårdsindustrin. Exempel på lösningar inkluderar egenutvecklade molnbaserade tjänster, e-posthantering, mobila lösningar, samt säkerhets- och backuplösningar. Kunderna återfinns huvudsakligen inom hälsa och vård, finans och telekom. Bolaget etablerades ursprungligen 1997 och har sitt huvudkontor i Göteborg.

redeye.se              Carasent (Q3 Review): In good shape for exciting 2026    Redeye retains its positive view of Carasent following the Q3 report. Organic ARR growth remains solid, and margins are improving substantially. The company has several ongoing growth initiatives tha                             Carasents lönsamhetsvändning fortsätter på rätt spår.

Vilken mäklare? Kontakta den, så löser det sig nog.

Jag har Carasent ASA för flera tusen. Den handlas inte längre så jag sitter fast med aktierna. Jag trodde att det skulle ha varit ett automatiskt byte till Carasent AB… är någon annan i samma situation? Vad ska jag göra? Hur förhindrar man sådant här i framtiden?

redeye.se              Carasent: Back in Shape in 2024 – More to Come    Redeye retains its positive view of Carasent following the Q4 report. Despite a somewhat softer Q4 report than expected and a softened outlook for H1 2025, we changed our Base Case driven by revised                              Nytt basfall SEK28 (NOK26.5)  Vi höjer vårt basfall till SEK28 (NOK26.5) på grund av en något lägre WACC, höjda marginalantaganden på medellång och lång sikt, samt ett större förtroende för den långsiktiga TAM-utsikten i Sverige. Med en värdering på cirka 3.6x försäljning 2025e kanske Carasent inte ser så attraktivt ut, med tanke på dess svaga LTM-marginaler. Vi tror dock att Carasent är redo för en betydande marginalexpansion under de närmaste åren. Med en R40 som närmar sig 30-35% under 2026-2027, tillsammans med en mycket låg churn och en icke-cyklisk slutmarknad, tror vi att Carasents värdering skulle kunna närma sig R40 SaaS-företag som tenderar att värderas till 6-8x försäljning NTM (exklusive Fortnox).

https://www.carnegie.se/en/commissioned-research/carasent/  ja https://www.redeye.se/research/1075597/carasent-q4-slightly-softer-than-expected?notificationId=61f17d48-fdd1-4433-a34a-fe6c54d3ae16

Redeye förväntningar inför kvartalsrapporten den 13.2.

Carnegielta beställde forskning inför Q4                   Inderes              Carnegie Access: Carasent: We expect a solid end to the year – Q4 preview -...    Carnegie has published a new commissioned research report on Carasent.To access the full report and subscribe to future updates, visit https://www.carnegie.se/en/commissioned-research/carasent...

Carasent

The Administrative Court has today rejected the appeal filed by several private care providers in primary care to remove the requirement for Millennium in primary care.The Administrative Court...

<div class="mfn-preamble"><p><strong>The Administrative Court has today rejected the appeal filed by several private care providers in primary care to remove the requirement for Millennium in primary care.</strong></p></div><div class="mfn-body"><p>The Administrative Court writes regarding the principle of proportionality:</p><p>No evidence has been presented to support that the examples of procedure proposed by the Companies are less intrusive than the introduction of the requirement. The fact that the proposed solutions on the part of the Companies offer an equivalent alternative to the requirement does not lead to the conclusion that the requirement is not necessary to achieve the intended purpose.</p><p>Comment from Carasent CEO, Daniel Öhman:</p><p>"My impression now is that most private care providers in primary care in VGR believe that they will avoid Millennium, but I would still be surprised if they do not appeal. The Administrative Court does not question that it is possible to achieve VGR's goal without forcing everyone into the same system, but it says that it has not been proven that integration with existing systems is less intrusive than forcing everyone into Millennium. This should be quite obvious and easy to show in the next instance."</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/f9f638bb-38b6-422d-b9d3-c57175f642a4/the-administrative-court-rejects-the-healthcare-providers-appeal-to-remove-the-requirement-for-millennium-in-primary-care-in-vgr.pdf" class="mfn-generated mfn-primary">The Administrative Court rejects the healthcare providers' appeal to remove the requirement for Millennium in primary care in VGR</a></p></div>